EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access

Weight Loss, Obesity Medication, and Risk of Obesity‐Associated Cancer: A Meta‐Analysis of Randomized Controlled Trials

Chengwen Li iD, Chu Lin iD, Xiaoling Cai iD, Fang Lv iD, Wenjia Yang, Linong Ji iD

Obesity · 2026-09 · 34 (S2) · 16-24

DOI: 10.1002/oby.70054 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Obesity, online erschienen am 04.11.2025. Verfasst von Chengwen Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Neoplasms, Obesity, Weight Loss. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Clinical Medicine Plus X-Young Scholars Project of Peking University, Fundamental Research Funds for the Central Universities, Noncommunicable Chronic Diseases-National Science and Technology Major Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to determine whether weight reduction mediated by antiobesity medications (AOMs) contributes to the risk reduction in obesity‐associated cancer.

Methods

PubMed, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, and the ClinicalTrials.gov website were systematically searched for randomized controlled trials of AOMs from inception to December 2024. Relative risks were calculated using a random‐effects model.

Results

The analysis included 25 randomized controlled trials with 40,731 participants. Compared with placebo, AOMs showed no association with the risk of overall obesity‐related cancer (RR = 1.03, 95% CI: 0.78 to 1.37) or site‐specific cancer. Consistently, every 5 kg weight reduction mediated by AOMs was not associated with the risk of overall obesity‐related cancer (RR = 0.97, 95% CI: 0.84 to 1.12) or site‐specific cancer. However, subgroup analysis revealed that coagonists (tirzepatide, cotadutide, and cagrilintide) significantly reduced overall obesity‐associated cancer risk (RR = 0.43, 95% CI: 0.19 to 0.97), and every 5 kg weight reduction mediated by coagonists was marginally associated with a reduced overall obesity‐associated cancer risk (RR = 0.79, 95% CI: 0.62 to 1.00).

Conclusions

Weight reduction mediated by current AOMs was not associated with a reduced risk of overall or site‐specific obesity‐associated cancer in patients with overweight or obesity, while a decreased risk of overall obesity‐associated cancer was observed in coagonist users.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Obesity AgentsNeoplasmsObesityWeight LossHumansRandomized Controlled Trials as TopicRisk Factors

Stichwörter der Autor:innen

meta‐analysisobesity medicationobesity‐associated cancerweight loss

Substanzen

Anti-Obesity Agents

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China.

ORCID-Profile: Chengwen Li, Chu Lin, Xiaoling Cai, Fang Lv, Linong Ji

Förderung

  • Clinical Medicine Plus X-Young Scholars Project of Peking University
  • Fundamental Research Funds for the Central Universities
  • Noncommunicable Chronic Diseases-National Science and Technology Major Project
  • 2024 National Clinical Key Specialty Construction Program of China

Zitieren

APA

Li, C., Lin, C., Cai, X., Lv, F., Yang, W., & Ji, L. (2026). Weight Loss, Obesity Medication, and Risk of Obesity‐Associated Cancer: A Meta‐Analysis of Randomized Controlled Trials. Obesity, 34(S2), 16-24. https://doi.org/10.1002/oby.70054

Vancouver

Li C, Lin C, Cai X, Lv F, Yang W, Ji L. Weight Loss, Obesity Medication, and Risk of Obesity‐Associated Cancer: A Meta‐Analysis of Randomized Controlled Trials. Obesity. 2026;34(S2):16-24. doi:10.1002/oby.70054

BibTeX
@article{Li2026,
  author = {Li, Chengwen and Lin, Chu and Cai, Xiaoling and Lv, Fang and Yang, Wenjia and Ji, Linong},
  title = {Weight Loss, Obesity Medication, and Risk of Obesity‐Associated Cancer: A Meta‐Analysis of Randomized Controlled Trials},
  journal = {Obesity},
  year = {2026},
  volume = {34},
  number = {S2},
  pages = {16--24},
  doi = {10.1002/oby.70054}
}
Kostenlos starten →